Perrigo Predicts Cough/Cold Sales Drop Due To Pseudoephedrine BTC Move
This article was originally published in The Tan Sheet
Executive Summary
Perrigo's cough/cold sales will likely be hurt in fiscal 2006 as retailers restrict pseudoephedrine products to behind-the-counter sale, according to the firm
You may also be interested in...
A Lesson In Exclusivity? Claritin Falters As Generic Loratadine Sales Double
The absence of Hatch/Waxman exclusivity for Schering-Plough's nonprescription Claritin has cost the company millions in potential revenue despite the drug's position as the most successful Rx-to-OTC switch to date
PLMA In Brief
Perrigo: Private labeler unveils Nasal Decongestant PE (phenylephrine 10 mg) in preparation for launch in the first half of 2005 at the Private Label Manufacturers Association trade show in Chicago Nov. 14-16. The 18-count tablets offer a decongestant alternative to solid tablet pseudoephedrine, Perrigo says. However, the product will face competition from same-ingredient private-label entries by Leiner and PL Developments, also slated to debut in early 2005 (see 1following story). Perrigo additionally plans pseudoephedrine 30 mg liquid caps and 15 mg grape-flavored syrup, as well as several new acetaminophen products for introduction in the in the first half of the year. The Allegan, Mich.-based firm also features Century Carb Multi (comparable to Wyeth's Centrum Carb Assist) in 45-tablet bottles and a store brand nutritional drink with plant sterols (equivalent to Abbott Labs' Ensure) in 6-8 oz. cans at the show...
Perrigo Moves In On Major Generic Firms With Agis Acquisition
Perrigo's acquisition of Israeli generic drug firm Agis Pharmaceuticals will put the combined entity's annualized sales over the $1 bil. mark and in the same league with major Rx generic drug players